Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints for Oncology Studies
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men Wit
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - ScienceDirect
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
Cancers | Free Full-Text | Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children | NEJM
Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram
KoreaMed
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review | Leukemia
Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma | Bone & Joint
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - ScienceDirect
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS | NEJM Evidence
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL | Leukemia
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Educational Sessions: "Approving new therapies for early breast cancer" - YouTube
Survival (time to event) Outcomes | Health Knowledge
